Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05089331 · ClinicalTrials.gov registry record
ROSE-Longitudinal Assessment With Neuroimaging
A clinical trial of Intracerebral Hemorrhage, sponsored by State University of New York at Buffalo.
- Recruiting
- Registry status
- 250
- Enrollment target
- 7
- Study locations
NCT05089331 is a study of Intracerebral Hemorrhage that is actively recruiting participants, run by State University of New York at Buffalo. The registered enrollment target is 250 participants, below the 1,167-participant average among 29 other Intracerebral Hemorrhage trials with a reported enrollment target (79% lower). The trial reports 7 study locations across 7 states.
The verdict
NCT05089331, a study of Intracerebral Hemorrhage, is actively recruiting participants, sponsored by State University of New York at Buffalo.
- RECRUITING
- Registry status
- 250 participants
- Enrollment target
- 7
- Study locations
Study Summary
The investigators will perform follow-up on 250 of 500 cases recruited into the ROSE study of cases with deep and lobar intracerebral hemorrhage to perform advanced neuroimaging at 12-24 months post stroke, and evaluations of motor and cognitive function at baseline, 6 months after baseline, and 12 months after baseline to determine predictors of recovery, progressive cognitive or functional impairment. The investigators propose to leverage the recruitment, DNA, RNA-seq and baseline advanced neuroimaging cohort of ROSE to obtain long-term neuroimaging and identical assessments longitudinally to address critical questions regarding the progressive decline of patients 12 to 24 months post intracerebral hemorrhage (ICH) with long term cognitive follow-up to 36 months on average. This proposal would represent the largest, and longest advanced neuroimaging and RNA-sequencing evaluation after ICH to date.
Conditions Studied
Study Locations (7)
Illinois
- University of Illinois Chicago - Chicago
Kentucky
- Baptist Health Louisville - Louisville
Maryland
- University of Maryland - Baltimore
New York
- Columbia University - New York
North Carolina
- Duke University - Durham
Ohio
- University of Cincinnati - Cincinnati
Texas
- Houston Methodist - Houston
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 250 participants |
| Start Date | 2020-09-30 |
| Est. Completion | 2026-06-01 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05089331
The ClinicalTrials.gov registry entry for NCT05089331 describes a study currently listed as recruiting, categorized as an unspecified phase. The registered enrollment target is 250 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 1,167-participant average among 29 other Intracerebral Hemorrhage trials with a reported enrollment target (79% lower). The listed sponsor is State University of New York at Buffalo, which has 243 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Intracerebral Hemorrhage appearing as the primary indexed condition, and to 0 interventions.
NCT05089331 reports 7 study locations spanning 7 distinct geographic areas - top geographies include Illinois, Kentucky, Maryland.
Frequently Asked Questions
What is clinical trial NCT05089331 about?
NCT05089331 is a clinical study titled "ROSE-Longitudinal Assessment With Neuroimaging". The investigators will perform follow-up on 250 of 500 cases recruited into the ROSE study of cases with deep and lobar intracerebral hemorrhage to perform advanced neuroimaging at 12-24 months post stroke, and evaluations of motor and cognitive function at baseline, 6 months after baseline, and 12 ...
What is the current status of trial NCT05089331?
This trial is currently recruiting. The enrollment target is 250 participants. The study started on 2020-09-30. Estimated completion is 2026-06-01.
What conditions does trial NCT05089331 study?
This clinical trial studies the following conditions: Intracerebral Hemorrhage.
Who is sponsoring clinical trial NCT05089331?
This trial is sponsored by State University of New York at Buffalo, which has 243 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05089331 being conducted?
This trial has 7 study locations across Illinois, Kentucky, Maryland, New York, North Carolina. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Intracerebral Hemorrhage
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Hemodynamic ABI Monitor
RECRUITING
-
Determinants of Incident Stroke Cognitive Outcomes and Vascular Effects on RecoverY
RECRUITING
-
Recombinant Factor VIIa (rFVIIa) for Hemorrhagic Stroke Trial - Part 2
RECRUITING · Phase 3
-
Transitions of Care for Stroke Patients
RECRUITING
-
International Care Bundle Evaluation in Cerebral Hemorrhage Research
RECRUITING · Phase 4
-
Optical Coherence Tomography Angiography in Neurological Disease
RECRUITING
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.